Literature DB >> 17302183

Tumor promotion as a target of cancer prevention.

Friedrich Marks1, Gerhard Fürstenberger, Karin Müller-Decker.   

Abstract

Tumor promotion is an essential process in multistage cancer development providing the conditions for clonal expansion and genetic instability of preneoplastic and premalignant cells. It is caused by a continuous disturbance of cellular signal transduction that results in an overstimulation of metabolic pathways along which mediators of cell proliferation and inflammation as well as genotoxic by-products are generated. Among such pathways the oxidative metabolism of arachidonic acid has turned out to be of utmost importance in tumor promotion. The aberrant overexpression of cyclooxygenase-2, an inducible enzyme of prostanoid synthesis and lipid peroxidation, is a characteristic feature of more than two-thirds of all human neoplasias, and the specific inhibition of this enzyme has been found to have a substantial chemopreventive effect in both animal models and man. The prostaglandins produced by COX-2 promote tumor development by stimulating cell proliferation and angiogenesis and by suppressing programmed cell death and immune defense. In mice, a COX-2 transgene fused with the keratin 5 promoter, which is constitutively active in the basal (proliferative) compartment of stratified and simple epithelia, causes a preneoplastic and premalignant phenotype in several organs. Among these organs, skin, mammary gland, urinary bladder, and pancreas have been investigated in more detail. Histologically and biochemically, the COX-2-dependent alterations resemble an autopromoted state that--as shown for skin and urinary bladder--strongly sensitizes the tissue for carcinogenesis. In transgenic animals COX-2 expression is not restricted to keratin 5-positive cells but is seen also in adjacent keratin 5-negative cells. This spreading of the COX-2 signal indicates a paracrine mechanism of autoamplification. While cancer chemoprevention by COX-2 inhibition is a rapidly developing field, much less is known about other pathways of unsaturated fatty acid metabolism, although some of them may play a role in carcinogenesis rivaling that of prostaglandin formation. Here an urgent demand for systematic research exists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302183     DOI: 10.1007/978-3-540-37696-5_3

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  12 in total

Review 1.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

2.  A smoking-based carcinogenesis model for lung cancer risk prediction.

Authors:  Millennia Foy; Margaret R Spitz; Marek Kimmel; Olga Y Gorlova
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

3.  An Overview of Ultraviolet B Radiation-Induced Skin Cancer Chemoprevention by Silibinin.

Authors:  Rahul Kumar; Gagan Deep; Rajesh Agarwal
Journal:  Curr Pharmacol Rep       Date:  2015-06-01

4.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

5.  The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.

Authors:  Carol D Mikulec; Joyce E Rundhaug; Melissa S Simper; Ronald A Lubet; Susan M Fischer
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

6.  Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.

Authors:  Olfat Ali Hammam; Ahmed A Aziz; Mamdouh S Roshdy; Ahmed M Abdel Hadi
Journal:  Medscape J Med       Date:  2008-03-11

7.  Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression.

Authors:  Mazin A Al-Salihi; A Terrece Pearman; Thao Doan; Ethan C Reichert; Daniel W Rosenberg; Stephen M Prescott; Diana M Stafforini; Matthew K Topham
Journal:  Cancer Lett       Date:  2008-09-14       Impact factor: 8.679

Review 8.  Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.

Authors:  Stephen G Grant; Melissa A Melan; Jean J Latimer; Paula A Witt-Enderby
Journal:  Expert Rev Mol Med       Date:  2009-02-05       Impact factor: 5.600

9.  Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model.

Authors:  Jianfeng Liu; Xin Gu; Delira Robbins; Guohong Li; Runhua Shi; Joe M McCord; Yunfeng Zhao
Journal:  PLoS One       Date:  2009-04-22       Impact factor: 3.240

10.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.